GLP1RAs Tied to Greater Risk of Diabetic Retinopathy Progression Than SGLT2is
Medically reviewed by Drugs.com.
By Lori Solomon HealthDay Reporter
FRIDAY, July 26, 2024 -- In patients with diabetes and established diabetic retinopathy (DR), treatment with glucagon-like peptide 1 receptor agonists (GLP1RAs) is associated with increased risks of DR progression compared with sodium-glucose cotransporter 2 inhibitors (SGLT2is), according to a study published online July 19 in Diabetes, Obesity and Metabolism.
Donna Shu-Han Lin, M.D., from Shin Kong Wu Ho-Su Memorial Hospital in Taipei, Taiwan, and colleagues examined the effects of GLP1RAs and SGLT2is on the development or progression of DR. Analysis included 1,517 patients treated with a GLP1RA with DR and 9,549 without DR and 3,034 patients treated with an SGLT2i with DR and 19,098 without DR.
The researchers found that in patients with preexisting DR, the incidence of any DR progression event was significantly higher in the GLP1RA group than the SGLT2i group (subdistribution hazard ratio, 1.50). This risk of progression was driven by increased risk of tractional RD. In patients without DR at baseline, the groups had similar risk for all ocular outcomes.
"The hazards of retinal events associated with GLP1RA use are probably accentuated in those with a higher baseline risk; whether this is related to more rapid glycemic control with GLP1RA use remains to be elucidated," the authors write.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-07-27 01:15
Read more
- FDA Grants Accelerated Approval to Ziihera (zanidatamab-hrii) for the Treatment of HER2-Positive Biliary Tract Cancer
- ACAAI: 2013 to 2023 Saw Rise in Pediatric Psych Referrals Tied to Food Allergies
- 'Dawson's Creek' Star James Van Der Beek Has Colon Cancer
- Long-Term Complications After Prostate Cancer Treatment Not Uncommon
- ACG: Hormone Therapy Tied to Higher Risk for New Irritable Bowel Syndrome
- In-Utero Sugar Restriction Cuts Offspring's Risk for Diabetes, Hypertension
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions